May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Epigallocatechin Gallate (ECGC) Administrated via Drinking Water Attenuates Light and Ischemic Insults to the Rat Retina
Author Affiliations & Notes
  • N. N. Osborne
    Nuffield Lab of Ophthalmology, University of Oxford, Oxford, United Kingdom
  • G.-Y. Li
    Nuffield Lab of Ophthalmology, University of Oxford, Oxford, United Kingdom
  • R. Safa
    Nuffield Lab of Ophthalmology, University of Oxford, Oxford, United Kingdom
  • K. D. Kang
    Nuffield Lab of Ophthalmology, University of Oxford, Oxford, United Kingdom
  • B. Zhang
    Nuffield Lab of Ophthalmology, University of Oxford, Oxford, United Kingdom
  • R. Fawcett
    Nuffield Lab of Ophthalmology, University of Oxford, Oxford, United Kingdom
  • B. L. A. Costa
    Nuffield Lab of Ophthalmology, University of Oxford, Oxford, United Kingdom
  • Footnotes
    Commercial Relationships  N.N. Osborne, None; G. Li, None; R. Safa, None; K.D. Kang, None; B. Zhang, None; R. Fawcett, None; B.L.A. Costa, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 6109. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N. N. Osborne, G.-Y. Li, R. Safa, K. D. Kang, B. Zhang, R. Fawcett, B. L. A. Costa; Epigallocatechin Gallate (ECGC) Administrated via Drinking Water Attenuates Light and Ischemic Insults to the Rat Retina. Invest. Ophthalmol. Vis. Sci. 2008;49(13):6109. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To deduce whether EGCG, a component of green tea, can affect light or ischemia/reperfusion (IR) injuries to the rat retina when present in drinking water.

Methods: : Ischemia was delivered to one eye of adult albino rats by elevation of intraocular pressure (120 mmHg) for 50 minutes. A light insult (2200 lux) was given to other rats for 24 hours. EGCG (0.4%) was present in some drinking water three days before and 3-5 days after an insult. Electroretinograms were recorded before and 4-5 days after an insult. Rats were killed 1-2 days later and retinas processed for immunohistochemistry and/or DNA breakdown (TUNEL). Retinal mRNA and protein levels of defined antigens were determined by RT-PCR and western blotting. Moreover, optic nerve neurofilament-light (NF-L) and tubulin content were determined for rats given IR.

Results: : IR or light insults caused a drastic reduction of the a- and b-wave amplitudes of electroretinograms and blunted significantly (n = 6-10, p< 0.01) by EGCG treatment. Photoreceptors were particularly affected (TUNEL positive cells in the outer nuclear layer and a reduction in photoreceptor specific protein, Ret-P1 and the mRNA rhodopsin) by a light insult accompanied by an up-regulation of GFAP. EGCG significantly attenuated (n= 8-16, p < 0.05) the light-induced changes to retinal proteins and mRNAs. Unlike a light insult, IR caused a clear alteration of certain inner retinal antigens that were attenuated by EGCG. Moreover, in vehicle-treated rats, IR caused a decrease in protein/mRNA levels of antigens associated with ganglion cells (Thy-1, NF-L, melanopsin) that were significantly (n = 8, p<0.05) counteracted by EGCG. In addition, IR caused a reduction in optic nerve NF-L and tubulin proteins that were significantly (n = 10, p<0.05) less reduced in EGCG treated animals.

Conclusions: : EGCG has a broad spectrum of neuroprotective properties which includes it being a powerful antioxidant. EGCG is well tolerated and crosses cell barriers easily. The present studies show that it reaches significant concentrations in the retina when given orally to attenuate insults of IR or light to the rat retina.

Keywords: antioxidants • apoptosis/cell death • ischemia 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×